Sequenta Presents Key Data at the 2011 American Society of Hematology Annual Meeting

December 5, 2011

SAN FRANCISCO, Dec 05, 2011 -- Sequenta, Inc., will present the results from five studies at the American Society of Hematology (ASH) annual meeting in San Diego, CA, December 10-12, 2011. The posters demonstrate significantly higher sensitivity of the company's Immune Cell Receptor Sequencing (ICRS) platform in detecting Minimal Residual Disease in Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples compared to standard of care technologies. The data presented also shows a significant correlation between the presence of these cells and clinical relapse.

Sequenta's five poster presentations at the ASH conference include data highlighting the use of noninvasive ICRS technology to accurately assess the disease state by counting cancer cells in circulation in four disease states.

The following poster presentations will be made during the conference by Sequenta and its collaborators:

Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results will be presented Sunday, December 11, 2011: 6:00 PM-8:00 PM, #3068. J. Brody, D. Czerwinski, (Stanford), V. Carlton (Sequenta), M. Moorhead (Sequenta), J. Zheng (Sequenta), M. Klinger (Sequenta), M. Faham, R. Advani (Stanford), H. Kohrt (Stanford), A. Alizadeh (Stanford), R. Negrin (Stanford), W. Weng (Stanford), K. Sheehan (Stanford) and R. Levy (Stanford).

Massively Parallel Immunoglobulin Gene Sequencing Provides Ultra-Sensitive Minimal Residual Disease Detection and Predicts Post-Transplant Relapse in Acute Lymphoblastic Leukemia by Three to Six Months will be presented Monday, December 12, 2011, #4104: 6:00 PM-8:00 PM. A. Logan (Stanford), N. Vashi (Stanford), M. Faham (Sequenta), V. Carlton (Sequenta), I. Bino (Hospital GU Maranon), J. Zheng (Sequenta), M. Klinger (Sequenta), T. Willis (Sequenta), M. Zhang (Stanford), A. Waqar (Stanford), J. Zehnder (Stanford) and D. Miklos (Stanford).

High-Throughput Immunoglobulin Gene Sequencing Quantifies Minimal Residual Disease in CLL with 10e-6 Sensitivity and Strongly Predicts Relapse After Allogeneic Hematopoietic Cell Transplantation will be presented Sunday, December 11, 2011, #2542: 6:00 PM-8:00 PM A. Logan (Stanford), M. Faham (Sequenta), V. Carlton (Sequenta), J. Zheng (Sequenta), M. Moorhead (Sequenta), T. Willis (Sequenta), C. Jones (Stanford), M. Zhang (Stanford), A. Waqar (Stanford), J. Zehnder (Stanford) and D. Miklos (Stanford).

Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region in Diagnostic Samples of Pediatric Acute Lymphoblastic Leukemia Identifies Hundreds of Clonal Subpopulations with Multiple Immunophenotypes will be presented Saturday, December 10, 2011: 5:30 PM-7:30 PM, #1436. C. Gawad (Stanford), M. Faham (Sequenta), T. Willis (Sequenta), M. Moorhead (Sequenta), V. Carlton (Sequenta), J. Zheng (Sequenta), M. Klinger (Sequenta), G. Dahl (Stanford) and N. Lacayo (Stanford).

Highly Sensitive Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia Using Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region will be presented Sunday, December 11, 2011: 6:00 PM-8:00 PM, #2540. M. Faham (Sequenta), T. Willis (Sequenta), M. Moorhead (Sequenta), V. Carlton (Sequenta), J. Zheng (Sequenta), and D. Campana (St. Jude).

About Sequenta Inc.
Sequenta, Inc. is a privately held company developing and commercializing molecular diagnostic assays based on a proprietary sequencing approach to the profiling of T and B cell receptor repertoires. The incredible diversity created by these genes is at the heart of a large number of conditions critical to human health and disease.

The company was founded in 2008 by Tom Willis and Malek Faham, two entrepreneurs who previously founded ParAllele BioScience, a company that developed and commercialized genomic technologies. ParAllele was acquired by Affymetrix in 2005. Sequenta's investors include Mohr Davidow and Index Ventures. The company is based in San Francisco, Calif., More information can be found at www.sequentainc.com .